This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (May 2020) |
Company type | Public |
---|---|
Nasdaq Stockholm: SOBI | |
Industry | Pharmaceutical |
Headquarters | Stockholm, Sweden |
Key people | |
Products | Treatments in the areas of haematology, immunology and specialty care |
Revenue | SEK 18.8 bn (2022)[1] |
SEK 14.4 bn (2022)[1] | |
Total assets | SEK 52.5 bn (2022)[1] |
Total equity | SEK 26.5 bn (2022)[1] |
Number of employees | 1,600 (2022)[1] |
Parent | Investor AB (34.7%)[1] |
Website | sobi.com |
Footnotes / references [1] |
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.
In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees.[2][3]